![Tom Powles on the NADINA trial](https://oncodaily.com/pub/uploads/2024/03/tom-e1719421772525.png)
Photo of Tom Powles taken from bartscancer.london
May 23, 2024, 13:04
Tom Powles on the NADINA trial
Tom Powles, Director of Barts Cancer Center, shared a post on X:
“The NADINA trial of neoadjuvant ipi/nivo vs adjuvant nivo in melanoma is a plenary ASCO24 . Shorter periods of therapy in responders (neoadjuvant alone) is an important question. Neoadjuvant nivo didn’t work in RCC (PROSPER). PACIFIC2 struggled in lung.”
Read further.
Source: Tom Powles/X
Aug 11, 2024, 05:36
Aug 11, 2024, 05:12
Aug 11, 2024, 04:55
Aug 11, 2024, 04:37
Aug 11, 2024, 02:26